Humacyte [HUMA] vs Cg Oncology [CGON] Detailed Stock Comparison
Humacyte
NASDAQ
Loading...
Cg Oncology
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Humacyte wins in 5 metrics, Cg Oncology wins in 9 metrics, with 2 ties. Cg Oncology appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Humacyte | Cg Oncology | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.13 | -23.48 | Cg Oncology |
| Price-to-Book Ratio | 56.15 | 3.52 | Cg Oncology |
| Debt-to-Equity Ratio | 2,072.16 | 0.15 | Cg Oncology |
| PEG Ratio | 0.02 | -0.25 | Cg Oncology |
| EV/EBITDA | -2.67 | -9.71 | Cg Oncology |
| Profit Margin (TTM) | 0.00% | 0.00% | Tie |
| Operating Margin (TTM) | -9,876.08% | -28,546.10% | Humacyte |
| Return on Equity | 282.33% | -12.00% | Humacyte |
| Return on Assets (TTM) | -50.18% | -11.66% | Cg Oncology |
| Free Cash Flow (TTM) | $-99.69M | $-78.95M | Cg Oncology |
| 1-Year Return | -72.87% | -13.09% | Cg Oncology |
| Price-to-Sales Ratio (TTM) | 282.67 | 4,281.49 | Humacyte |
| Enterprise Value | $277.16M | $1.53B | Cg Oncology |
| EV/Revenue Ratio | 338.82 | 2,769.44 | Humacyte |
| Gross Profit Margin (TTM) | 29.24% | N/A | N/A |
| Revenue per Share (TTM) | $0 | $0 | Tie |
| Earnings per Share (Diluted) | $-0.47 | $-1.78 | Humacyte |
| Beta (Stock Volatility) | 1.87 | N/A | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Humacyte vs Cg Oncology Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Humacyte | -2.05% | -7.74% | -38.10% | -45.42% | -54.60% | -72.39% |
| Cg Oncology | 6.88% | 23.30% | 22.75% | 24.18% | 23.26% | 14.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Humacyte | -72.87% | -68.29% | -85.42% | -85.42% | -85.42% | -85.42% |
| Cg Oncology | -13.09% | -5.60% | -5.60% | -5.60% | -5.60% | -5.60% |
Performance & Financial Health Analysis: Humacyte vs Cg Oncology
| Metric | HUMA | CGON |
|---|---|---|
| Market Information | ||
| Market Cap | $226.47M | $2.36B |
| Market Cap Category | Micro cap | Mid cap |
| 10 Day Avg. Volume | 3,522,930 | 612,939 |
| 90 Day Avg. Volume | 5,555,147 | 691,970 |
| Last Close | $1.43 | $33.07 |
| 52 Week Range | $1.15 - $6.77 | $14.80 - $40.47 |
| % from 52W High | -78.88% | -18.29% |
| All-Time High | $17.45 (Aug 30, 2021) | $50.23 (Feb 12, 2024) |
| % from All-Time High | -91.81% | -34.16% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.42% | -1.00% |
| Quarterly Earnings Growth | N/A | -1.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.00% |
| Operating Margin (TTM) | -98.76% | -285.46% |
| Return on Equity (TTM) | 2.82% | -0.12% |
| Debt to Equity (MRQ) | 2,072.16 | 0.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.03 | $8.79 |
| Cash per Share (MRQ) | $0.24 | $8.67 |
| Operating Cash Flow (TTM) | $-104,498,000 | $-93,817,000 |
| Levered Free Cash Flow (TTM) | $-72,620,872 | $396.48M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Humacyte vs Cg Oncology
| Metric | HUMA | CGON |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.13 | -23.48 |
| Forward P/E | -1.70 | -17.38 |
| PEG Ratio | 0.02 | -0.25 |
| Price to Sales (TTM) | 282.67 | 4,281.49 |
| Price to Book (MRQ) | 56.15 | 3.52 |
| Market Capitalization | ||
| Market Capitalization | $226.47M | $2.36B |
| Enterprise Value | $277.16M | $1.53B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 338.82 | 2,769.44 |
| Enterprise to EBITDA | -2.67 | -9.71 |
| Risk & Other Metrics | ||
| Beta | 1.87 | N/A |
| Book Value per Share (MRQ) | $0.03 | $8.79 |
Financial Statements Comparison: Humacyte vs Cg Oncology
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | HUMA | CGON |
|---|---|---|
| Revenue/Sales | $301,000 | $52,000 |
| Cost of Goods Sold | $213,000 | N/A |
| Gross Profit | $88,000 | N/A |
| Research & Development | $22.01M | $27.47M |
| Operating Income (EBIT) | $-29.73M | $-42.20M |
| EBITDA | $-27.04M | $-42.18M |
| Pre-Tax Income | $-37.66M | $-34.45M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $-37.66M | $-34.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | HUMA | CGON |
|---|---|---|
| Cash & Equivalents | $62.85M | $41.47M |
| Total Current Assets | $73.71M | $701.19M |
| Total Current Liabilities | $20.03M | $22.64M |
| Long-Term Debt | $12.84M | $781,000 |
| Total Shareholders Equity | $36.04M | $704.76M |
| Retained Earnings | $-646.88M | $-252.43M |
| Property, Plant & Equipment | $44.64M | $1.30M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | HUMA | CGON |
|---|---|---|
| Operating Cash Flow | $-11.80M | $-28.85M |
| Capital Expenditures | $-228,000 | $-16,000 |
| Free Cash Flow | $-28.83M | $-29.29M |
| Debt Repayment | $-687,000 | $0 |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | HUMA | CGON |
|---|---|---|
| Shares Short | 34.25M | 10.33M |
| Short Ratio | 6.17 | 11.25 |
| Short % of Float | 0.25% | 0.14% |
| Average Daily Volume (10 Day) | 3,522,930 | 612,939 |
| Average Daily Volume (90 Day) | 5,555,147 | 691,970 |
| Shares Outstanding | 130.03M | 76.15M |
| Float Shares | 125.19M | 61.28M |
| % Held by Insiders | 0.20% | 0.01% |
| % Held by Institutions | 0.36% | 1.13% |
Dividend Analysis & Yield Comparison: Humacyte vs Cg Oncology
| Metric | HUMA | CGON |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |